News

Combining OSI Pharmaceuticals’s Integrated Lead Discovery platform with BioTrove’s RapidFire mass spectrometry-based assay development, screening and analysis services, the agreement will enable customers to pursue challenging drug targets

The combined technologies will be available for use by customers using the TrialMaster, First in Functionality, electronic data capture (EDC) solution. The collaboration will allow customers that are

Under the terms of its 1997 license agreement with Cook, Angiotech is entitled to receive royalty payments upon the commercial sale of paclitaxel-eluting peripheral vascular stent products, including

The URG101-104 study was a pharmacodynamic and safety study investigating the treatment of painful bladder syndrome or interstitial cystitis (PBS/IC). The cross-over design utilized provided sufficient power to

Varian acquired Oxford Diffraction for approximately $37 million in cash and assumed net debt. The transaction also includes an opportunity for additional purchase price payments over three years,

The state-of-the-art facility, utilizing the strictest operational and quality standards, will produce key brands of Wyeth nutritional products for infants and toddlers, including formula and milk products sold

Under the terms of the agreement, PerkinElmer will exclusively market Cerep’s target screening and profiling services to its customers, and the companies will jointly promote PerkinElmer’s assay technologies

The approval decision follows a positive opinion adopted on 21 February 2008 by the European Committee for Medicinal Products for Human Use (CHMP). The CHMP submission is based

Total proceeds from the sale, including excess cash in the business, are expected to be $165 million, subject to working capital adjustments. The completion of the transaction is